The Correlation of BRCA 1 Promoter Methylation and Clinicopathological Appearance in Breast Cancer
AbstractBreast cancer is one of the common cancers in the worldwide. Most of breast cancer are sporadic. BRCA1 expression levels are reduced or totally loss in sporadic breast cancer. BRCA1 promoter methylation as one of the mechanisms to inactivating its function. BRCA1 promoter methylation associated with triple negative breast cancer (TNBC), poor prognosis, high grade, negativity of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2(HER2). This study aims are to examine prevalence and correlation between BRCA1 promoter methylation and clinicopathology appearance in Indonesian women breast cancer. Subject are women with primary breast cancer and their formalin-fixed paraffin -embedded (FFPE) tumor specimen retrieved.DNA was isolated and subjected to methylation specific PCR(MSPCR). DNA was isolated from primary tumor of 113 samples. Median age at diagnosis was 48 years (with range 28-80 years). Most of them, 67(59,3%) are include in aged categories <50 years. Incidence BRCA promoter methylation was found 82,3% (93 of 113.) There is significant correlation with BRCA1 promoter methylation with age<50 years old (p-value = 0.038) and Luminal B subtype (p-value = 0.033). Conclusion: BRCA1 promoter methylation in Indonesian women higher than other nations, correlate with younger patient and Luminal B subtype.
J. Ferlay et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” Int. J. Cancer, vol. 136, no. 5, pp. E359-386, Mar. 2015.
M. Wahidin, R. Noviani, S. Hermawan, V. Andriani, A. Ardian, and H. Djarir, “Population-Based Cancer Registration in Indonesia,” Asian Pac. J. Cancer Prev., vol. 13, no. 4, pp. 1709–1710, Apr. 2012.
R. D. Kennedy, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin, “The Role of BRCA1 in the Cellular Response to Chemotherapy,” JNCI J. Natl. Cancer Inst., vol. 96, no. 22, pp. 1659–1668, Nov. 2004.
C. R. Mueller and C. D. Roskelley, “Regulation of BRCA1 expression and its relationship to sporadic breast cancer,” Breast Cancer Res., vol. 5, no. 1, pp. 45–52, 2003.
A. Catteau and J. R. Morris, “BRCA1 methylation: a significant role in tumour development?,” Semin. Cancer Biol., vol. 12, no. 5, pp. 359–371, Oct. 2002.
M. Esteller et al., “Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors,” JNCI J. Natl. Cancer Inst., vol. 92, no. 7, pp. 564–569, Apr. 2000.
O. A. Stefansson et al., “CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer,” Epigenetics, vol. 6, no. 5, pp. 638–649, May 2011.
A. M. Dworkin, T. H.-M. Huang, and A. E. Toland, “Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment,” Semin. Cancer Biol., vol. 19, no. 3, pp. 165–171, Jun. 2009.
L. Zhang and X. Long, “Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies,” Sci. Rep., vol. 5, p. 17869, Dec. 2015.
A. Bal et al., “BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression,” Virchows Arch. Int. J. Pathol., vol. 461, no. 3, pp. 305–312, Sep. 2012.
Y. Xu et al., “Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy,” Ann. Oncol., vol. 24, no. 6, pp. 1498–1505, Jun. 2013.
P. Sharma et al., “The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer,” J. Cancer Ther. Res., vol. 3, no. 2, pp. 1–11, Mar. 2014.
E. Honrado et al., “Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families,” Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc, vol. 20, no. 12, pp. 1298–1306, Dec. 2007.
N. C. Hsu, Y.-F. Huang, K. K. Yokoyama, P.-Y. Chu, F.-M. Chen, and M.-F. Hou, “Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer,” PloS One, vol. 8, no. 2, p. e56256, 2013.
X. Xu et al., “BRCA1 Promoter Methylation is Associated with Increased Mortality among Women with Breast Cancer,” Breast Cancer Res. Treat., vol. 115, no. 2, pp. 397–404, May 2009.
M. E. H. Hammond et al., “American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer,” J. Clin. Oncol., vol. 28, no. 16, pp. 2784–2795, Jun. 2010.
A. C. Wolff et al., “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 31, no. 31, pp. 3997–4013, Nov. 2013.
A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann, and H.-J. Senn, “Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011,” Ann. Oncol., vol. 22, no. 8, pp. 1736–1747, Aug. 2011.
P. Porter, “‘Westernizing’ Women’s Risks? Breast Cancer in Lower-Income Countries,” N. Engl. J. Med., vol. 358, no. 3, pp. 213–216, Jan. 2008.
S. Solikhah, S. Promthet, N. Rakkapao, and C. P. Hurst, “Validation of an Indonesian Version of the Breast Cancer Awareness Scale (BCAS-I),” Asian Pac. J. Cancer Prev. APJCP, vol. 18, no. 2, pp. 515–522, 2017.
R. D. Nindrea, W. A. Harahap, T. Aryandono, and L. Lazuardi, “Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis,” Asian Pac. J. Cancer Prev. APJCP, vol. 19, no. 4, pp. 885–889, 2018.
V. Birgisdottir, O. A. Stefansson, S. K. Bodvarsdottir, H. Hilmarsdottir, J. G. Jonasson, and J. E. Eyfjord, “Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer,” Breast Cancer Res., vol. 8, no. 4, p. R38, 2006.
J. S. Lee et al., “A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women,” Cancer Biol. Ther., vol. 6, no. 7, pp. 1114–1120, Jul. 2007.
J. Mehrotra et al., “Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women,” Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., vol. 10, no. 6, pp. 2052–2057, Mar. 2004.
M. M. Hosny, N. A. Sabek, T. B. El-Abaseri, F. M. Hassan, and S. H. Farrag, “Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients,” International Journal of Breast Cancer, 2016. [Online]. Available: https://www.hindawi.com/journals/ijbc/2016/9545241/. [Accessed: 27-Jul-2018].
A. A. Hashmi et al., “Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients,” World J. Surg. Oncol., vol. 16, Jan. 2018.
L. A. Carey, “Directed Therapy of Subtypes of Triple-Negative Breast Cancer,” The Oncologist, vol. 16, no. Supplement 1, pp. 71–78, Jan. 2011.
Z. Li, P. Hu, J. Tu, and N. Yu, “Luminal B breast cancer: patterns of recurrence and clinical outcome,” Oncotarget, vol. 7, no. 40, pp. 65024–65033, Aug. 2016.
Prihantono, P., Hatta, M., Binekada, C., Sampepajung, D., Islam AA, and Nilawati Usman, A. Ki-67 expression by immunohistochemistry and quantitative real-time polymerase chain reaction as predictor of clinical response to neoadjuvant chemotherapy in locally advanced breast cancer. J Oncol. 2017: 6209849. doi: 10.1155/2017/6209849
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.